Evidence map›Paper›PMID 39492626›Full record

ArticleHistology and histopathology2025

Associations between BCL-2 expression and different histopathological prognostic factors in different molecular subtypes of invasive breast carcinoma of no special type.

Wael Abdo Hassan, Mohamed El-Assmy, Ahmed Kamal ElBanna, Ihab Harbieh, Noha Noufal, Hany Lotfy, Tarek Abdelaziz Hasan Shemais, Ossama Ashour Haikal, Mostafa Magdy Saber, Rehab Ibrahim Ali

Abstract read
PubMed Publisher
In one paragraph

Article in Histology and histopathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wael Abdo HassanDepartment of Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt. w.hassan@sr.edu.sa.
Mohamed El-AssmyDepartment of Clinical Sciences, Sulaiman Al Rajhi University, Al Bukayriyah, Saudi Arabia.
Ahmed Kamal ElBannaDepartment of Basic Sciences, Faculty of Medicine, Sulaiman Al Rajhi University, Al Bukayriyah, Saudi Arabia.
Ihab HarbiehDepartment of Basic Sciences, Faculty of Medicine, Sulaiman Al Rajhi University, Al Bukayriyah, Saudi Arabia.
Noha NoufalDepartment of Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
Hany LotfyDepartment of Basic Sciences, Faculty of Medicine, Sulaiman Al Rajhi University, Al Bukayriyah, Saudi Arabia.
Tarek Abdelaziz Hasan ShemaisDepartment of Basic Sciences, Faculty of Medicine, Sulaiman Al Rajhi University, Al Bukayriyah, Saudi Arabia.
Ossama Ashour HaikalDepartment of Clinical Sciences, Sulaiman Al Rajhi University, Al Bukayriyah, Saudi Arabia.
Mostafa Magdy SaberMedical Oncology Department, Faculty of Medicine, Port Said University, Egypt.
Rehab Ibrahim AliDepartment of Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBreast cancer is heterogeneous and the existing prognostic classifiers are limited in accuracy, leading to the unnecessary treatment of numerous women. B-cell lymphoma 2 (BCL-2), an anti-apoptotic protein, has been proposed as a marker of poor prognosis, associated with resistance to therapy in most tumor types expressing BCL-2. In breast cancer, however, BCL-2 expression has been reported to be a favorable prognostic factor. This study aimed to describe the association between BCL-2 and other well-known pathological prognostic markers among different molecular sub-types of invasive breast carcinoma of no special type (IBC; NST).

methodsBCL-2 expression, as well as that of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), were immunohistochemically (IHC) evaluated and compared with other pathological factors, including tumor size, grade, tumor-infiltrating lymphocytes (TILs), lymph-vascular invasion (LVI), and lymph node (LNd) metastasis, in 128 breast cancer cases diagnosed with IBC; NST. Moreover, we analyzed the correlation between BCL-2 expression and relapse-free survival (RFS) in all patients over a two-year period.

resultsWe found that BCL-2 expression had different pathological prognostic factor associations with different molecular subtypes of breast carcinoma. In the luminal A (i.e., hormonal receptor-positive and HER2-negative) and triple-negative subtypes, the expression of BCL-2 in tumor cells was significantly associated with tumor size, tumor grade, and TILs. BCL2-positive expression in luminal IBC; NST patients resulted in a significantly favorable two-year survival.

conclusionBCL-2 expression in IBC; NST has different prognostic effects depending on the molecular subtype of the cancer. In cancers with a HER2-enriched phenotype, BCL-2 expression was a marker of poor prognosis, while in cancers with a hormone receptor-positive phenotype, BCL-2 expression had a better prognostic impact.

Indexed as

Biomarkers, TumorBreast NeoplasmsProto-Oncogene Proteins c-bcl-2AdultAgedAged, 80 and overDisease-Free SurvivalErb-b2 Receptor Tyrosine KinasesFemaleHumansImmunohistochemistryMiddle AgedNeoplasm InvasivenessPrognosisReceptors, EstrogenReceptors, ProgesteroneBCL2 protein, humanBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesProto-Oncogene Proteins c-bcl-2Receptors, EstrogenReceptors, Progesterone

Identifiers

PMID39492626

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.